Cargando…
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Following the first proof of concept of using small nucleic acids to modulate gene expression, a long period of maturation led, at the end of the last century, to the first marketing authorization of an oligonucleotide-based therapy. Since then, 12 more compounds have hit the market and many more ar...
Autores principales: | Moumné, Lara, Marie, Anne-Céline, Crouvezier, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876811/ https://www.ncbi.nlm.nih.gov/pubmed/35213992 http://dx.doi.org/10.3390/pharmaceutics14020260 |
Ejemplares similares
-
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
por: Dhuri, Karishma, et al.
Publicado: (2020) -
STING as an emerging therapeutic target for drug discovery: Perspectives from the global patent landscape
por: Kong, Xiangjun, et al.
Publicado: (2022) -
Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023) -
Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers
por: Yu, Yuanyuan, et al.
Publicado: (2016) -
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
por: Imran, Mohd., et al.
Publicado: (2021)